House mark-up continues good prospects for FDA in FY 22. The Alliance reacts positively to the House Subcommittee mark for FDA.
House mark-up continues good prospects for FDA in FY 22. The Alliance reacts positively to the House Subcommittee mark for FDA. Upcoming Webinars - Associate Commissioner for Regulatory Affairs (ACRA) Judy McMeekin, July 14; CDRH Director Jeff Shuren, July 22.
I often start Hill meetings by asking staffers when they were last in a meeting where consumers and industry came in the door together and delivered a joint message in support of a federal agency.
I often start Hill meetings by asking staffers when they were last in a meeting where consumers and industry came in the door together and delivered a joint message in support of a federal agency. It is a powerful message for everyone we meet with that FDA is special and worthy of their support. It is also a unique experience for many of them to see consumers and industry together.
Appropriations bills are delayed but set to begin moving. Getting a budget resolution (or, at a minimum, a measure to "deem" a discretionary allocation to the appropriations committees) is key.
Appropriations bills are delayed but set to begin moving. Getting a budget resolution (or, at a minimum, a measure to "deem" a discretionary allocation to the appropriations committees) is key. Final appropriations action is uncertain. Upcoming Alliance webinars - Associate Commissioner for Regulatory Affairs (ACRA) Judy McMeekin (July 14) and CDRH Director Jeff Shuren (July 22).